GlassScriptPhysician profile
Iqbal Dhanani
NPI 1972674190
$9,234.12
in general payments reported to CMS, 2019-2025
20 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $875 · 2021: $1,446 · 2022: $1,415 · 2023: $807 · 2024: $1,234 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,226.84 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,812.45 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,376.86 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,158.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $805.12 | 2024-2025 | Ingrezza |
| Abbvie INC. | $628.29 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $577.17 | 2020-2025 | Caplyta |
| Alkermes, INC. | $488.92 | 2019-2024 | Lybalvi, Vivitrol |
| Allergan, INC. | $254.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $250.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $172.62 | 2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $153.12 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $108.19 | 2020-2022 | |
| Lundbeck LLC | $97.09 | 2020-2021 | |
| Noven Therapeutics, LLC | $80.77 | 2020-2021 | |
| Indivior INC. | $78.10 | 2019-2023 | Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.20 | 2022 | |
| Bausch Health US, LLC | $45.86 | 2021 | |
| Merck Sharp & Dohme LLC | $33.96 | 2020 | |
| Axsome Therapeutics, INC. | $33.80 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $24.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Dhanani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.